IRVINE, Calif., April 9, 2009 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced the launch of an additional model of its SenoSonix(tm) System. Like the original SenoSonix, the new model is an integration of SenoRx's EnCor(r) breast biopsy system with ultrasound imaging. This new version of the device incorporates a microminiaturization ultrasound technology that combines personal computing power and flexibility. The new ultrasound component is designed, developed and manufactured by Terason, a division of Teratech Corporation, based in Burlington, Massachusetts. This versatile and unique ultrasound technology coupled with SenoRx's proprietary EnCor vacuum-assisted biopsy technology results in an attractive alternative model of the SenoSonix System for our customers. The modular design and sophisticated imaging architecture are now available in a reduced footprint with increased portability. The SenoSonix System received 510(k) clearance in October 2007 and CE Mark approval in April 2008.
"Our new SenoSonix model is designed to meet the needs of breast surgeons performing breast biopsy procedures utilizing ultrasound in both their offices and in the hospital surgery suite who wish to have the flexibility of moving the ultrasound component between the two locations," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "The new system may be particularly well suited for markets in Europe and Asia where a significant percentage of biopsy procedures are performed utilizing ultrasound. We are pleased to be working with Terason on this compact portable solution. We will begin introducing this product in the U.S. and in select countries in which we have launched the EnCor breast biopsy system."
"We are happy to be partnering with SenoRx on this new initiative," said Dr. Alice Chiang, Terason Chief Executive Officer. "SenoRx is a leader in their market segment and, like Terason, has been innovative in enhancing patient care using ultrasound image guidance."
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605
About Terason
Terason is an innovator and a world leader in integrating patented ultrasound microsystem technology with a commercial laptop. This unique system-on-a-chip architecture provides high performance and cost effective ultrasound solution to the point of patient care, and enables other imaging suppliers to embed it into their technology. Terason is entrusted by thousands of clinicians and partners throughout the world for ultrasound diagnosis and interventional guidance. For more information on Terason please visit www.terason.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning expected benefits and usage of our products are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Information on potential risk factors that could affect SenoRx's business and its financial results are detailed in its most recent quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.